127 related articles for article (PubMed ID: 31441600)
21. Long non-coding RNA MEG3 as a candidate prognostic factor for induction therapy response and survival profile in childhood acute lymphoblastic leukemia patients.
Gao W
Scand J Clin Lab Invest; 2021 May; 81(3):194-200. PubMed ID: 33600264
[TBL] [Abstract][Full Text] [Related]
22. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood.
Coutinho DF; Monte-Mór BC; Vianna DT; Rouxinol ST; Batalha AB; Bueno AP; Boulhosa AM; Fernandez TS; Pombo-de-Oliveira MS; Gutiyama LM; Abdelhay E; Zalcberg IR
Leuk Res; 2015 Oct; 39(10):1103-8. PubMed ID: 26277372
[TBL] [Abstract][Full Text] [Related]
23. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia.
Roman-Gomez J; Jimenez-Velasco A; Cordeu L; Vilas-Zornoza A; San Jose-Eneriz E; Garate L; Castillejo JA; Martin V; Prosper F; Heiniger A; Torres A; Agirre X
Eur J Cancer; 2007 Dec; 43(18):2736-46. PubMed ID: 18032022
[TBL] [Abstract][Full Text] [Related]
24. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
25. High expression of Musashi-2 indicates poor prognosis in adult B-cell acute lymphoblastic leukemia.
Mu Q; Wang Y; Chen B; Qian W; Meng H; Tong H; Chen F; Ma Q; Ni W; Chen S; Jin J
Leuk Res; 2013 Aug; 37(8):922-7. PubMed ID: 23759245
[TBL] [Abstract][Full Text] [Related]
26. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group.
Borkhardt A; Cazzaniga G; Viehmann S; Valsecchi MG; Ludwig WD; Burci L; Mangioni S; Schrappe M; Riehm H; Lampert F; Basso G; Masera G; Harbott J; Biondi A
Blood; 1997 Jul; 90(2):571-7. PubMed ID: 9226156
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
Santamaría C; Ramos F; Puig N; Barragán E; de Paz R; Pedro C; Insunza A; Tormo M; Del Cañizo C; Diez-Campelo M; Xicoy B; Salido E; Sánchez del Real J; Hernández M; Chillón C; Sanz GF; García-Sanz R; San Miguel JF; González M
Ann Hematol; 2012 Dec; 91(12):1887-95. PubMed ID: 22875062
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Implication of MIF Gene Expression in Childhood Acute Lymphoblastic Leukemia.
Sharaf-Eldein M; Elghannam D; Elderiny W; Abdel-Malak C
Clin Lab; 2018 Sep; 64(9):1429-1437. PubMed ID: 30274020
[TBL] [Abstract][Full Text] [Related]
29. Wilms tumor gene single nucleotide polymorphism rs16754 predicts a favorable outcome in children with acute lymphoblastic leukemia.
Junghanns AS; Wittig S; Woehlecke C; Lehmann T; Arndt C; Gruhn B
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2221-8. PubMed ID: 26224397
[TBL] [Abstract][Full Text] [Related]
30. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of the Effect of TET2 Mutation and SNP on Clinical Characteristics and Prognosis of AML Patients].
Li L; An LC; Chu XX; Liu XQ; Wang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):453-459. PubMed ID: 32319378
[TBL] [Abstract][Full Text] [Related]
32. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
33. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
34. Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
[TBL] [Abstract][Full Text] [Related]
35. 5-Hydroxymethylcytosine expression is associated with poor survival in cervical squamous cell carcinoma.
Zhang LY; Han CS; Li PL; Zhang XC
Jpn J Clin Oncol; 2016 May; 46(5):427-34. PubMed ID: 26851753
[TBL] [Abstract][Full Text] [Related]
36. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
[TBL] [Abstract][Full Text] [Related]
37. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
38. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
Nibourel O; Kosmider O; Cheok M; Boissel N; Renneville A; Philippe N; Dombret H; Dreyfus F; Quesnel B; Geffroy S; Quentin S; Roche-Lestienne C; Cayuela JM; Roumier C; Fenaux P; Vainchenker W; Bernard OA; Soulier J; Fontenay M; Preudhomme C
Blood; 2010 Aug; 116(7):1132-5. PubMed ID: 20489055
[TBL] [Abstract][Full Text] [Related]
39. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract][Full Text] [Related]
40. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
Mohamed AM; Balsat M; Koering C; Maucort-Boulch D; Boissel N; Payen-Gay L; Cheok M; Mortada H; Auboeuf D; Pinatel C; El-Hamri M; Tigaud I; Hayette S; Dumontet C; Cros E; Flandrin-Gresta P; Nibourel O; Preudhomme C; Thomas X; Nicolini FE; Solly F; Guyotat D; Campos L; Michallet M; Ceraulo A; Mortreux F; Wattel E
Leuk Res; 2017 May; 56():21-28. PubMed ID: 28167452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]